JNJ

Rating neutralAI MemoPost-earnings T+1

Johnson Johnson

As of 2026-10-14/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

December Enterprise Business Review tests the 2027 outlook • 2026-12-08

Base target: $268 / p=45% prob

Biggest risk

Management acknowledged MedTech missed its expectations, particularly Cardiovascular and Surgery outside the U.S.; ABIOMED physician selectivity remains a headwind. Q3 GAAP EPS fell to $0.09, and the proposed $5.5 billion ovarian-talc resolution is conditional on participation by at least 95% of remaining claims. The separate J&J–Kenvue evidence describes talc-liability retention and indemnification, not a quantified current guarantee exposure. [#REL-4e39b5f7-7661-4ff7-8079-48247ded3ee6] J&J prepared remarks

Invalidation

Break below $210 or thesis failure.

What would change my mind?

Innovative Medicine grew 7.9% operationally despite an approximately 690-basis-point STELARA drag; management identified TREMFYA, myeloma therapies, SPRAVATO and CAPLYTA as drivers. ICOTYDE uptake and OTTAVA authorization add identifiable growth routes, while the 2026 guidance midpoint rose modestly. The announced Sail in vivo CAR-T collaboration is a longer-term pipeline option, not a quantified near-term earnings contribution and remains conditional. [#REL-d45f6068-b685-482f-8fcd-677e1acc85c9] J&J prepared remarks

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-14

Base target

$268

p=45%

Bull target

$300

p=30%

Bear target

$210

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 medicine strength versus MedTech disappointment
OTTAVA launch and orthopaedics separation execution
Innovative Medicine grew 7.9% operationally despite an approximately 690-basis-point STELARA drag; management identified TREMFYA, myeloma therapies, SPRAVATO and CAPLYTA as drivers.

BearKey bullets

Firefly Bio and Sail Biomedicines investments dilute adjusted EPS; management projected a combined $1.36-per-share effect in 2027.
MedTech grew only 2.5% operationally in Q3, below management's expectations; Cardiovascular and Surgery outside the U.S.
need improvement.

WatchKey bullets

December Enterprise Business Review tests the 2027 outlook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $268 (p=45%)

Target spread vs base: +12% / -22%

Scenario probabilities

Bull Target: $300 (p=30%)Base Target: $268 (p=45%)Bear Target: $210 (p=25%)

Commentary

The first post-print read is mixed: Q3 revenue and 2026 guidance rose, but MedTech missed management's expectations and JNJ closed October 13 at $248.61, down 5.73%. Coverage linked the selloff to the talc charge and MedTech weakness. No reliable post-print analyst target-change series is available, and conflicting consensus snapshots limit surprise precision; zero values in unobserved sentiment fields are placeholders, not measured readings. historical close market coverage

As of 2026-10-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 medicine strength versus MedTech disappointment
OTTAVA launch and orthopaedics separation execution

Scenarios

Bull Target (Scenario probability)

$300 / p=30% prob

Base Target (Scenario probability)

$268 / p=45% prob

Bear Target (Scenario probability)

$210 / p=25% prob

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-08
December Enterprise Business Review tests the 2027 outlook
After lifting its 2026 reported-sales midpoint to $101.2 billion and adjusted-EPS midpoint to $11.10, J&J said its December 8 review will add detail on 2027, the early-stage pipeline and its path to double-digit growth by decade-end. The event is more consequential than the small Q3 guidance increase itself. [#SEC-8K-2026-10-13] J&J prepared remarks
Prob 75.00% • Move 5.00% • Priced-in 45.00%
EVENT2026-12-31
Specific Q4 oncology and MedTech milestones
Management expects Q4 data for pasritamig and JNJ-6143 in prostate cancer, an INLEXZO bladder-cancer readout, and U.S. decisions for RYBREVANT FASPRO in head-and-neck cancer and VARIPULSE Pro. These are program-specific opportunities, not assured approvals or revenue. J&J prepared remarks
Prob 65.00% • Move 4.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Q3 medicine strength versus MedTech disappointment
2026-10-31
Q3 sales rose 5.9% to $25.399 billion and adjusted EPS was $2.59, but MedTech operational growth was only 2.5%; management said the segment fell short of its expectations. Reported EPS was $0.09 after special charges, including the proposed talc resolution and business-development deals. The market must decide whether stronger Innovative Medicine growth can offset the device weakness. [#8-K-2026-10-13] [#SEC-8K-2026-10-13] SEC earnings exhibit
Prob 65% • Move 3% • Priced-in 65%

Long-term Catalysts

Months to a year

OTTAVA launch and orthopaedics separation execution
2027-06-30
J&J reports its first OTTAVA commercial customer following FDA De Novo authorization, but expects adoption and revenue to build over time. Management still targets a DePuy Synthes separation by mid-2027 and currently leans toward a spin; neither adoption scale nor separation completion is established. J&J prepared remarks
Prob 60% • Move 7% • Priced-in 45%

Risks

Firefly Bio and Sail Biomedicines investments dilute adjusted EPS; management projected a combined $1.36-per-share effect in 2027.
MedTech grew only 2.5% operationally in Q3, below management's expectations; Cardiovascular and Surgery outside the U.S. need improvement.
OTTAVA commercialization, future indications, Q4 readouts, regulatory decisions and the planned orthopaedics separation carry execution risk.
STELARA biosimilar erosion reduced Innovative Medicine growth by approximately 690 basis points in Q3, while other established brands also declined.
The proposed ovarian-talc resolution remains conditional on sufficient claimant participation; litigation outcomes and ultimate cash costs remain uncertain.

Peers

Symbol	Summary
ABBV	Direct branded-immunology and oncology comparator for judging whether TREMFYA, ICOTYDE and J&J's oncology portfolio can outrun STELARA erosion; it does not replicate J&J's MedTech exposure.
MRK	Large-cap innovative-medicines comparator for oncology growth and patent-cycle risk; J&J's device and litigation exposures make a simple multiple comparison incomplete.
AZN	Global biopharma comparator for oncology and specialty-medicine growth, but without J&J's MedTech mix.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-14

Loading AI feed…

Symbol

Summary

ABBV

Direct branded-immunology and oncology comparator for judging whether TREMFYA, ICOTYDE and J&J's oncology portfolio can outrun STELARA erosion; it does not replicate J&J's MedTech exposure.

MRK

Large-cap innovative-medicines comparator for oncology growth and patent-cycle risk; J&J's device and litigation exposures make a simple multiple comparison incomplete.

AZN

Global biopharma comparator for oncology and specialty-medicine growth, but without J&J's MedTech mix.